Canada - English - Health Canada

apotex inc - capecitabine - tablet - 150mg - capecitabine 150mg - antineoplastic agents

Canada - English - Health Canada

apotex inc - capecitabine - tablet - 500mg - capecitabine 500mg - antineoplastic agents

Canada - English - Health Canada

mint pharmaceuticals inc - capecitabine - tablet - 150mg - capecitabine 150mg - antineoplastic agents

Canada - English - Health Canada

mint pharmaceuticals inc - capecitabine - tablet - 500mg - capecitabine 500mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

United States - English - NLM (National Library of Medicine)

cipla usa inc. - capecitabine (unii: 6804dj8z9u) (capecitabine - unii:6804dj8z9u) - - capecitabine tablets usp is indicated as a single agent for adjuvant treatment in patients with dukes' c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. capecitabine was non-inferior to 5- fluorouracil and leucovorin (5-fu/lv) for disease-free survival (dfs). physicians should consider results of combination chemotherapy trials, which have shown improvement in dfs and os, when prescribing single-agent capecitabine in the adjuvant treatment of dukes' c colon cancer. - capecitabine tablets usp are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. combination chemotherapy has shown a survival benefit compared to 5-fu/lv alone. a survival benefit over 5-fu/lv has not been demonstrated with capecitabine tablets monotherapy. use of capecitabine tablets usp instead o

United States - English - NLM (National Library of Medicine)

msn laboratories private limited - capecitabine (unii: 6804dj8z9u) (capecitabine - unii:6804dj8z9u) - - capecitabine tablets usp is indicated as a single agent for adjuvant treatment in patients with dukes’ c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. capecitabine was non-inferior to 5-fluorouracil and leucovorin (5-fu/lv) for disease-free survival (dfs). physicians should consider results of combination chemotherapy trials, which have shown improvement in dfs and os, when prescribing single-agent capecitabine in the adjuvant treatment of dukes’ c colon cancer. - capecitabine tablets usp are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. combination chemotherapy has shown a survival benefit compared to 5-fu/lv alone. a survival benefit over 5-fu/lv has not been demonstrated with capecitabine tablets monotherapy. use of capecitabine tablets usp instead of 5-fu/lv in combinations has not been adequately studied to assur

United States - English - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - capecitabine (unii: 6804dj8z9u) (capecitabine - unii:6804dj8z9u) - - capecitabine tablets usp is indicated as a single agent for adjuvant treatment in patients with dukes’ c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. capecitabine was non-inferior to 5- fluorouracil and leucovorin (5-fu/lv) for disease-free survival (dfs). physicians should consider results of combination chemotherapy trials, which have shown improvement in dfs and os, when prescribing single-agent capecitabine in the adjuvant treatment of dukes’ c colon cancer. - capecitabine tablets usp are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. combination chemotherapy has shown a survival benefit compared to 5-fu/lv alone. a survival benefit over 5-fu/lv has not been demonstrated with capecitabine tablets monotherapy. use of capecitabine tablets usp instead of 5- fu/lv in combinations has not been adequately studied to ass

United States - English - NLM (National Library of Medicine)

areva pharmaceuticals - capecitabine (unii: 6804dj8z9u) (capecitabine - unii:6804dj8z9u) - - capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with dukes’ c colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. capecitabine tablets are non-inferior to 5-fluorouracil and leucovorin (5-fu/lv) for disease-free survival (dfs). physicians should consider results of combination chemotherapy trials, which have shown improvement in dfs and os, when prescribing single-agent capecitabine tablets in the adjuvant treatment of dukes’ c colon cancer. - capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. combination chemotherapy has shown a survival benefit compared to 5-fu/lv alone. a survival benefit over 5-fu/lv has not been demonstrated with capecitabine tablets monotherapy. use of capecitabine tablets instead of 5-fu/lv in combinations has not been adequately studied to